

Interlocutory Orders, Etc.

IN THE MATTER OF

**CHINA NATIONAL CHEMICAL CORPORATION,
ADAMA AGRICULTURAL SOLUTIONS LTD.,
AND
MAKHTESHIM AGAN OF NORTH AMERICA, INC. D/B/A ADAMA**

Docket No. C-4610. Order, November 28, 2018

Letter approving the substitute monitor and the substitute monitor agreement.

LETTER ORDER APPOINTING MONITOR

Peter Guryan, Esq.
Simpson Thacher & Bartlett LLP

Re: *In the Matter of China National Chemical Corporation et al.*, Docket No. C-4610.

Dear Mr. Guryan:

This is to notify you that, pursuant to Paragraph IV.F. of the Decision and Order issued in *In the Matter of China National Chemical Corporation et al.*, Docket No. C-4610, the Federal Trade Commission has appointed Monitoring Trustee Partners B.V. as the substitute monitor and approved the substitute monitor agreement executed by Respondents and Monitoring Trustee Partners B.V.

By the direction of the Commission.

Interlocutory Orders, Etc.

Attachment

MONITOR AGREEMENT

This Monitor Agreement (this "Agreement"), entered into this 19 day of October, 2018, by and among Monitoring Trustee Partners B.V. ("MTP" or the "Monitor") and China National Chemical Corporation Limited, ADAMA Agricultural Solutions, Ltd., and Makhteshim Agan of North America, Inc. (collectively "ChemChina") (MTP and ChemChina together, the "Parties") provides as follows:

WHEREAS the Federal Trade Commission (the "Commission"), in the Matter of China National Chemical Corporation Limited, ADAMA Agricultural Solutions, Ltd., and Makhteshim Agan of North America, Inc., File No. 161-0093, has accepted or will shortly accept for public comment an Agreement Containing Consent Orders incorporating a Decision and Order and an Order to Maintain Assets (collectively, the "Orders"), which, among other things, requires ChemChina to divest certain pesticide assets, as defined in the Orders, and contemplates the appointment of a Monitor to monitor ChemChina's compliance with its obligations under the Orders;

WHEREAS, the Commission is expected to accept the Agreement Containing Consent Orders and appoint Monitor pursuant to the Orders to monitor ChemChina's compliance with the terms of the Orders, and Monitor has consented to such appointment;

WHEREAS, the Orders further provide that ChemChina shall execute an agreement, subject to the prior approval of the Commission, conferring all the rights and powers necessary to permit Monitor to carry out its duties and responsibilities pursuant to the Orders;

WHEREAS, this Agreement, although executed by Monitor and ChemChina, is not effective for any purpose, including but not limited to imposing rights and responsibilities on ChemChina or Monitor under the Orders, except for those obligations under the confidentiality provisions herein, until it has been approved by the Commission; and

WHEREAS, the Parties to this Agreement intend to be legally bound, subject only to the Commission's approval of this Agreement.

NOW, THEREFORE, the Parties agree as follows:

All capitalized terms used in this Agreement and not specifically defined herein shall have the respective definitions given to them in the Orders.

ARTICLE I

1.1 Powers of the Monitor. Monitor shall have all of the powers and responsibilities conferred upon Monitor by the Orders, including but not limited to monitoring ChemChina's compliance with the divestiture, asset maintenance obligations, and other related requirements of the Orders. The Monitor shall act in a fiduciary capacity for the benefit of the Commission.

1.2 Access to Relevant Information and Facilities. Subject to any demonstrated legally recognized privilege, Monitor shall have full and complete access to ChemChina's

Interlocutory Orders, Etc.

personnel, books, documents, records kept in the normal course of business, facilities and technical information, and such other relevant information as Monitor may reasonably request, related to ChemChina's compliance with the obligations of ChemChina under the Orders in this matter. Documents, records and other relevant information are to be provided in an electronic format if they exist in that form. ChemChina shall cooperate with any reasonable request of Monitor. Monitor shall give ChemChina reasonable notice of any request for such access or such information and shall attempt to schedule any access or requests for information in such a manner as will not unreasonably interfere with ChemChina's operations. At the request of the Monitor, ChemChina shall promptly arrange meetings and discussions, including tours of relevant facilities, at reasonable times and locations between the Monitor and employees of ChemChina who have knowledge relevant to the proper discharge of its responsibilities under the Orders.

1.3 Compliance Reports. ChemChina shall provide Monitor with copies of all compliance reports filed with the Commission in a timely manner, but in any event, no later than five (5) business days after the date on which ChemChina files such report with the Commission.

1.4 Confidentiality. Monitor shall:

(a) maintain the confidentiality of all confidential information provided to the Monitor by ChemChina, the acquirer of the CP Assets, any supplier or customer of ChemChina, or the Commission ("Confidential Information"), and shall use such information only for the purpose of discharging its obligations as Monitor and not for any other purpose, including, without limitation, any other business, scientific, technological, or personal purpose. Monitor may disclose Confidential Information only to (i) persons employed by or working with Monitor pursuant to the Orders or (ii) persons employed at the Commission or the European Commission;

(b) require any consultants, accountants, attorneys, and any other representatives and/or assistants retained by Monitor to assist in carrying out the duties and responsibilities of Monitor to execute a confidentiality agreement, which ChemChina will provide if requested, that requires such third parties to treat Confidential Information with the same standards of care and obligations of confidentiality to which the Monitor must adhere under this Agreement;

(c) maintain a record and inform the Commission of all third parties (other than representatives of the Commission) to whom Confidential Information has been disclosed;

(d) for a period of five (5) years after the termination of this Agreement, maintain the confidentiality of all other aspects of the performance of its duties under this Agreement and not disclose any Confidential Information relating thereto; and

(e) upon the termination of the Monitor's duties under this Agreement, the Monitor shall consult with the Commission's staff regarding disposition of any written and electronic materials (including materials that ChemChina provided to the Monitor) in the possession or control of the Monitor that relate to the Monitor's duties, and the Monitor shall dispose of such materials, which may include sending such materials to the Commission's staff, as directed by the staff. In response to a request by ChemChina to return or destroy materials that

Interlocutory Orders, Etc.

ChemChina provided to the Monitor, the Monitor shall inform the Commission's staff of such request and, if the Commission's staff do not object, shall comply with ChemChina's request. Notwithstanding the foregoing, the Monitor shall not be required to return or destroy confidential information contained in an archived computer back-up system for its disaster recovery and/or security purposes, and it may retain a copy of confidential information, subject to the terms of this Agreement, in accordance with its internal record retention procedures for legal or regulatory purposes. Nothing herein shall abrogate the Monitor's duty of confidentiality, which includes an obligation not to disclose any non-public information obtained while acting as a Monitor for ten (10) years after termination of this Agreement.

For the purpose of this Agreement, information shall not be considered confidential or proprietary to the extent that it is or becomes part of the public domain (other than as the result of any action by the Monitor or by any employee, agent, affiliate or consultant of the Monitor), or to the extent that the recipient of such information can demonstrate that such information was already known to the recipient at the time of receipt from a source other than the Monitor, ChemChina, or any director, officer, employee, agent, consultant or affiliate of the Monitor or ChemChina, when such source was not known to recipient after due inquiry to be restricted from making such disclosure to such recipient.

ARTICLE II

2.1 Retention and Payment of Counsel, Consultants, and other Assistants. Monitor shall have the authority to employ, at the cost and expense of the ChemChina, such attorneys, consultants, accountants, and other representatives and assistants as are reasonably necessary to carry out the Monitor's duties and responsibilities pursuant to the Orders. Prior to engaging any such parties and prior to commissioning additional work to be performed by a party who has already been so engaged, Monitor shall notify ChemChina of its intention to do so, and provide an estimate of the anticipated costs.

2.2 Monitor Compensation. ChemChina shall pay Monitor in accordance with the fee schedule and procedure attached as Confidential Appendix A for all reasonable time spent in the performance of the Monitor's duties, including all monitoring activities related to the efforts of the acquirer of the CP Assets, all work in connection with the negotiation and preparation of this Agreement, and all reasonable and necessary travel time.

(a) In addition, ChemChina shall pay: (i) all out-of-pocket expenses reasonably incurred by Monitor in the performance of its duties under the Orders; and (ii) all reasonable fees of, and disbursements reasonably incurred by, any advisor appointed by Monitor pursuant to the first paragraph in Article II.

(b) The Monitor shall have full and direct responsibility for compliance with all applicable laws, regulations and requirements pertaining to work permits, income and social security taxes, unemployment insurance, worker's compensation, disability insurance, and the like.

Interlocutory Orders, Etc.

2.3 Monitor's Indemnification: Limitation on Liability. ChemChina shall indemnify and hold harmless Monitor and its employees and agents against any losses, claims, damages, liabilities, or expenses arising out of, or in connection with, the performance of Monitor's duties, including all reasonable fees of counsel and other expenses incurred in connection with the preparation for, or defense of, any claim, whether or not resulting in any liability, except to the extent that such losses, claims, damages, liabilities, or expenses result from Monitor's gross negligence or willful misconduct. Monitor shall not be liable hereunder for any amount in excess of the fees paid to it, except in the event of Monitor's gross negligence, willful misconduct or fraud. Monitor shall not be liable hereunder for any incidental, consequential, special or punitive damages, regardless of whether it has been informed of the possibility thereof.

2.4 Disputes. In the event of a disagreement or dispute between ChemChina and Monitor concerning ChemChina's obligations under the Orders, and, in the event that such disagreement or dispute cannot be resolved by the Parties, either party may seek the assistance of the individual in charge of the Commission's Compliance Division.

2.5 Conflicts of Interest. In the event that, during the term of this Agreement, Monitor becomes aware it has or may have a conflict of interest that may affect, or could have the appearance of affecting, performance by Monitor or persons employed by, or working with, Monitor, of any of its duties under this Agreement, Monitor shall promptly inform ChemChina and the Commission of any such conflict or potential conflict.

ARTICLE III

3.1 Termination. This Agreement shall terminate the earlier of: (a) the expiration or termination of the Orders; (b) ChemChina's receipt of written notice from the Commission that the Commission has determined that Monitor has ceased to act or failed to act diligently, or is unwilling or unable to continue to serve as Monitor; (c) with at least thirty (30) days advance notice to be provided by Monitor to ChemChina and to the Commission, upon resignation of the Monitor; or (d) when the Monitor completes its Final Report pursuant to the Decision and Order; provided, however, that the Commission may require that ChemChina extend this Agreement as may be necessary or appropriate to accomplish the purposes of the Orders. If this Agreement is terminated for any reason, the confidentiality obligations set forth in this Agreement will remain in force, as will the provisions of Articles 2.2 and 2.3 of this Agreement.

3.2 Monitor's Removal. If the Commission determines that Monitor ceases to act or fails to act diligently and consistent with the purpose of the Orders, ChemChina shall, upon written request of the Commission, terminate this Agreement and appoint a substitute Monitor, subject to Commission approval and consistent with the Orders.

3.3 Governing Law. This Agreement and the rights and obligations of the Parties hereunder shall in all respects be governed by the substantive laws of the State of New York, including all matters of construction, validity and performance. The Orders shall govern this Agreement and any provisions herein which conflict or are inconsistent with the Orders may be declared null and void by the Commission and any provision not in conflict shall survive and remain a part of this Agreement.

Interlocutory Orders, Etc.

3.4 Disclosure of Information. Nothing in this Agreement shall require ChemChina to disclose any material or information that is subject to a legally recognized privilege or that ChemChina is prohibited from disclosing by reason of law or an agreement with a third party.

3.5 Assignment. This Agreement may not be assigned or otherwise transferred by ChemChina or Monitor without the consent of ChemChina and Monitor and the approval of the Commission. Any such assignment or transfer shall be consistent with the terms of the Orders.

3.6 Modification. No amendment, modification, termination, or waiver of any provision of this Agreement shall be effective unless made in writing, signed by all Parties, and approved by the Commission. Any such amendment, modification, termination, or waiver shall be consistent with the terms of the Orders.

3.7 Approval by the Commission. This Agreement shall have no force or effect until approved by the Commission, other than the Parties' obligations under the confidentiality provisions herein.

3.8 Entire Agreement. This Agreement, and those portions of the Orders incorporated herein by reference, constitute the entire agreement of the Parties and supersede any and all prior agreements and understandings between the Parties, written or oral, with respect to the subject matter hereof.

3.9 Duplicate Originals. This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same document.

3.10 Section Headings. Any heading of the sections is for convenience only and is to be assigned no significance whatsoever as to its interpretation and intent.

Interlocutory Orders, Etc.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date first above written.


MONITOR

Monitoring Trustee Partners



Jan Jaap Smid
Managing Director,
Monitoring Trustee Partners**Respondent**

China National Chemical Corporation Limited



Chen Hongbo
Executive Director, China National
Agrochemical Co. Limited

Interlocutory Orders, Etc.

IN THE MATTER OF

**WATSON PHARMACEUTICALS INC.,
ACTAVIS INC.,
ACTAVIS PHARMA HOLDING 4 EHF.,
AND
ACTAVIS S.Á.R.L.**

Docket No. C-4373. Order, December 17, 2018

Order granting the Petition of Teva Pharmaceutical Industries Ltd. as the successor to Watson Pharmaceuticals Inc. and Actavis Inc. to Reopen and Modify Decision and Order for the limited purpose of modifying and setting aside the Commission's Decision and Order, dated December 14, 2012, as it applies to Teva's agreement to supply the abuse-resistant opioid painkiller morphine sulphate naltrexone extended release capsules (brand name Embeda®) to Pfizer Inc.

ORDER REOPENING AND MODIFYING ORDER

On October 22, 2018, Teva Pharmaceutical Industries Ltd. ("Teva") filed a petition ("Petition") pursuant to Section 5(b) of the Federal Trade Commission Act, 15 U.S.C. § 45(b), and Section 2.51(b) of the Commission's Rules of Practice and Procedure, 16 C.F.R. § 2.51(b), requesting that the Commission reopen and modify the Commission's order in Docket No. C-4373 ("Order"). Teva is the successor to Watson Pharmaceuticals Inc. ("Watson") and Actavis Inc. ("Actavis"), the Respondents to the Order. Teva filed the Petition at the request of Pfizer Inc. ("Pfizer").

The Order remedied the anticompetitive effects in twenty-one pharmaceutical markets resulting from Watson's acquisition of Actavis, including the market for extended release acute pain treatment served by branded Embeda®,¹ which Pfizer and Actavis were developing and manufacturing prior to the acquisition pursuant to an exclusive agreement. At the time of the acquisition, Pfizer had recalled Embeda, but was planning to reintroduce it to the market after reformulating the product. Watson was one of only a few companies that appeared likely to enter with a generic version of Embeda. As part of the Commission's remedy, Watson/Actavis and Pfizer amended the Development and Manufacturing Services Agreement between Actavis and Pfizer ("Agreement") in several respects, including to remove impediments to entry by a generic Embeda (e.g., by eliminating Actavis' right of first refusal to market an authorized generic) and to foster Pfizer's relaunch of Embeda and eventual independence from supply from Actavis (e.g., by transferring manufacturing rights back to Pfizer). The Order provided that Pfizer would continue to have a supply of Embeda from Actavis to allow Pfizer to relaunch Embeda pursuant to the amended Agreement, but consistent with limiting continuing

¹ The Order refers to Embeda® as Morphine Sulphate Naltrexone Extended Release Products. Order ¶ I.FFF.